Clinical Trials Logo

Filter by:
NCT ID: NCT00669617 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Start date: April 2008
Phase: Phase 3
Study type: Interventional

This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg

NCT ID: NCT00669240 Completed - Smoking Cessation Clinical Trials

Varenicline Observational Investigation In The Cessation of Smoking

CHOICES
Start date: November 2007
Phase: N/A
Study type: Observational

The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being offered behavioral support "Life REWARDS"TM. This is a non-interventional study.

NCT ID: NCT00667823 Completed - Clinical trials for Pulmonary Arterial Hypertension

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

SERAPHIN OL
Start date: October 17, 2008
Phase: Phase 3
Study type: Interventional

The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.

NCT ID: NCT00665366 Completed - Clinical trials for Bipolar Disorder Mania

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

Start date: June 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.

NCT ID: NCT00664716 Completed - Clinical trials for Rheumatoid Arthritis

Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants

RESPOND
Start date: July 2007
Phase: Phase 2
Study type: Interventional

Safety and efficacy of BG9924 in RA participants that have had an inadequate response to disease-modifying anti-rheumatic drug (DMARD) therapy.

NCT ID: NCT00663052 Completed - Psoriasis Clinical Trials

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis

PRISTINE
Start date: June 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of different doses of etanercept for the treatment of moderate to severe psoriasis.

NCT ID: NCT00662649 Completed - Multiple Sclerosis Clinical Trials

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Start date: February 2008
Phase: Phase 3
Study type: Interventional

This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis. The Extension study was an extension to the 24-month Core study (CFTY720D2301/NCT00289978).

NCT ID: NCT00660881 Completed - Clinical trials for Systemic Lupus Erythematosus

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the safety of epratuzumab in patients with SLE.

NCT ID: NCT00660179 Completed - Clinical trials for Pulmonary Arterial Hypertension

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

SERAPHIN
Start date: May 2008
Phase: Phase 3
Study type: Interventional

The AC-055-302/SERAPHIN study will be an event-driven Phase III study, comparing two different doses of macitentan (ACT-064992) (3 and 10 mg) vs placebo in patients with symptomatic PAH. The main study objective is to demonstrate that macitentan (ACT-064992) prolongs time to the first morbidity or mortality event, and to evaluate the benefit/risk profile of macitentan (ACT-064992) in the treatment of patients with symptomatic PAH.

NCT ID: NCT00660023 Completed - Anemia Clinical Trials

A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis

Start date: August 2008
Phase: Phase 3
Study type: Interventional

This single-arm study will assess the efficacy and safety of monthly administration of intravenous methoxy polyethylene glycol-epoetin beta (CERA/Mircera) for the maintenance of hemoglobin (Hb) levels in participants on dialysis with chronic renal anemia in routine clinical practice in Hungary. Participants currently receiving maintenance treatment with intravenous epoetin or darbepoetin will receive monthly injections of Mircera, with the starting dose derived from the erythropoiesis-stimulating agent (ESA) dose they had been receiving.